Lipid-binding properties of synthetic peptide fragments of human apolipoprotein A-II

被引:8
作者
Benetollo, C
Lambert, G
Talussot, C
Vanloo, B
VanCauteren, T
Rouy, D
Dubois, H
Baert, J
Kalopissis, A
Denefle, P
Chambaz, J
Brasseur, R
Rosseneu, M
机构
[1] STATE UNIV GHENT,LAB LIPOPROT CHEM,DEPT BIOCHEM,B-9000 GHENT,BELGIUM
[2] INST BIOMED CORDELIERS,CJF 9508,INSERM,PARIS,FRANCE
[3] RHONE POULENC RORER,DIV ATHEROSCLEROSIS,VITRY SUR SEINE,FRANCE
[4] UNIV LEUVEN CAMPUS KORTRIJK,INTERDISCIPLINARY RES CTR,KORTRIJK,BELGIUM
[5] FAC AGRON GEMBLOUX,CTR BIOPHYS MOL NUMER,GEMBLOUX,BELGIUM
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 1996年 / 242卷 / 03期
关键词
peptide; apolipoprotein A-II; lipid; helix; circular dichroism;
D O I
10.1111/j.1432-1033.1996.0657r.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human apolipoprotein A-II (apo A-II) consists of three potential amphipathic helices of 17 residues each, which contribute to the lipid-binding, properties of this apolipoprotein. The conformation and lipid-binding properties of these peptides, either as-single-helix or as two-helix peptides, were investigated by turbidity, fluorescence, electron-microscopy and circular-dichroism measurements, and are compared in this article. The lipid affinity of shorter C-terminal segments of apo A-II was compared with those of the single-helix or two-helix peptides, to define the minimal peptide length required for stable complex formation. The properties of the apo-A-II-(13-48)-peptide were further compared with those of the same segment after deletion of the Ser31 and Pro32 residues, because the deleted apo-A-II-(13-30)-(33-48)-peptide, is predicted to form a long uninterrupted helix. The single helices of apo A-II could not form stable complexes with phospholipids, and the helix-turn-helix segment spanning-residues 13-48 was not active either. The apo-A-II-(37-77)-peptide and the apo-A-II-(40-73)-peptide could form complexes with lipids, which appear as discoidal particles by negative-staining electron microscopy. The shortest C-terminal domain of apo A-II, able to associate with lipids to form stable complexes was the apo-A-II-(40-73)-peptide, which consisted of the C-terminal helix, a beta-turn and part of the preceding helix. The shorter ape-A-II-(49-77)-peptide, and the helical ape-A-II-(13-30)-(33-48)-peptide, could also associate with phospholipids. The complexes formed were, however, less stable, as they dissociated outside the transition temperature range of the phospholipid. These data suggest that the C-terminal pair of helices of apo A-II, which is the most hydrophobic pair, is responsible for the lipid-binding properties of the entire protein. The N-terminal pair of helices of apo A-II at residues 13-48 does not associate tightly with lipids. The degree of internal similarity and the cooperativity between the helical segments of apo A-II is thus less pronounced than in apo A-I or apo A-IV. The N-terminal and C-terminal domains of apo A-II appear to behave as two distinct entities with regard to lipid-protein association.
引用
收藏
页码:657 / 664
页数:8
相关论文
共 42 条
[31]  
Pownall H. J., 1987, PLASMA LIPOPROTEINS, P95
[32]   ACTIVATION OF LECITHIN - CHOLESTEROL ACYLTRANSFERASE BY A SYNTHETIC MODEL LIPID-ASSOCIATING PEPTIDE [J].
POWNALL, HJ ;
HU, A ;
GOTTO, AM ;
ALBERS, JJ ;
SPARROW, JT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (06) :3154-3158
[33]  
ROSSENEU M, 1981, EUR J BIOCHEM, V117, P347, DOI 10.1111/j.1432-1033.1981.tb06344.x
[34]   PROTEIN-COMPOSITION DETERMINES THE ANTI-ATHEROGENIC PROPERTIES OF HDL IN TRANSGENIC MICE [J].
SCHULTZ, JR ;
VERSTUYFT, JG ;
GONG, EL ;
NICHOLS, AV ;
RUBIN, EM .
NATURE, 1993, 365 (6448) :762-764
[35]   AMPHIPATHIC HELIX MOTIF - CLASSES AND PROPERTIES [J].
SEGREST, JP ;
DELOOF, H ;
DOHLMAN, JG ;
BROUILLETTE, CG ;
ANANTHARAMAIAH, GM .
PROTEINS-STRUCTURE FUNCTION AND GENETICS, 1990, 8 (02) :103-117
[36]  
SPARROW JT, 1981, CRIT REV BIOCH, V13, P87
[37]   PLASMA HIGH-DENSITY LIPOPROTEINS - METABOLISM AND RELATIONSHIP TO ATHEROGENESIS [J].
TALL, AR .
JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (02) :379-384
[38]  
THUREN T, 1991, J BIOL CHEM, V266, P4853
[39]  
VANLOO B, 1991, J LIPID RES, V32, P1253
[40]  
VANLOO B, 1995, J LIPID RES, V36, P1501